All Phenotypes Npy2r<tm1Hhz> MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Npy2r^tm1Hhz/Npy2r^tm1Hhz	involves: 129X1/SvJ * C57BL/6	MGI:3694056
cn2	Npy^{tm1(rtTA,tetO-cre/EGFP)Snby}/Npy⁺ Npy2r^tm1Hhz/Npy2r^tm1Hhz	involves: 129X1/SvJ * C57BL/6	MGI:5297095

Allelic Composition	Npy2r^tm1Hhz/Npy2r^tm1Hhz
Genetic Background	involves: 129X1/SvJ * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Npy2r^tm1Hhz mutation (0 available); any Npy2r mutation (30 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:77345 )

N	• at 34 days after injection, leptinemia, insulinemia and glycemia are not significantly different from controls

abnormal circulating hormone level ( J:77345 )

increased circulating corticosterone level ( J:77345 , J:97455 )

• male, but not female hypothalamus-specific null mice, display corticosteronemia at 34 days post-injection (J:77345)

• in mice treated with a hypothalamus-specific cre (J:97455)

abnormal circulating insulin level ( J:77345 )

• at 12 days post-injection, insulinemia of hypothalamus-specific mutants tend toward lower values (58) than controls (97)

abnormal circulating pancreatic peptide level ( J:77345 )

• male, but not female, hypothalamus-specific knockouts show a four-fold increase in plasma pancreatic polypeptide (PP) levels 34 days after injection

skeleton

decreased osteoclast cell number ( J:97455 )

• in mice treated with a hypothalamus-specific cre

abnormal trabecular bone morphology ( J:97455 )

• in mice treated with a hypothalamus-specific cre, trabecular bone volume is increased 2-fold compared to in control mice

• in mice treated with a hypothalamus-specific cre, trabeculae number and thickness are increased compared to in control mice

increased trabecular bone thickness ( J:97455 )

• in mice treated with a hypothalamus-specific cre

increased bone mineralization ( J:97455 )

• in mice treated with a hypothalamus-specific cre, bone mineral apposition rate is increased 2-fold compared to in control mice

increased bone ossification ( J:97455 )

• in mice treated with a hypothalamus-specific cre, bone formation rate is increased 2-fold compared to in control mice

growth/size/body

decreased body weight ( J:77345 )

• 7-8 days after hypothalamic cre-recombinase injection, mutants display a drop in body weight compared to GFP-injected mice or cre-injected wild-type mice or mutants receiving cre injection in the CA3 region of the hippocampus; at 12 days post-injection, hypothalamus-specific null mutants weigh significantly less than controls

• recovery to initial body weight is significantly delayed in hypothalamus-specific null mice; male controls return to original body weight within 14-22 days, but male hypothalamic-null mice do not fully recover their body weight until 28 days while null females recover by 23 days post-injection compared to 16 days in control females

adipose tissue

adipose tissue phenotype ( J:77345 )

N	• hypothalamus-specific null mice do not show differences in white adipose tissue mass compared to controls

behavior/neurological

abnormal food intake ( J:77345 )

• male hypothalamus-specific null mice show significantly greater food intake than control mice after cre injection; female hypothalamus-null mutants show a similar tendency toward increased food intake

hematopoietic system

decreased osteoclast cell number ( J:97455 )

• in mice treated with a hypothalamus-specific cre

immune system

decreased osteoclast cell number ( J:97455 )

• in mice treated with a hypothalamus-specific cre

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

growth/size/body

growth/size/body region phenotype ( J:162000 )

N	• weight gain monitored over 8-week period and body length of mutants after cre induction by intracerebroventricular injection of doxycycline is not different from treated controls or wild-type mice

increased body fat mass ( J:162000 )

• by whole body densitometry (DEXA), whole body fat mass in doxycycline-treated females is increased compared to wild-type controls; however, expressed as percent body weight, whole fat mass in doxycycline-treated females is not different from saline-treated mutant females

increased susceptibility to weight gain ( J:162000 )

• analyses over a 2-day period by indirect calorimetry show that male mutants (after cre induction) display a significant increase in body weight compared to treated controls; this transient, significant positive weight gain is observed in females also

adipose tissue

increased body fat mass ( J:162000 )

decreased white adipose tissue mass ( J:162000 )

• doxycycline-treated females show a trend to reduced total fat (white adipose tissue) mass (as % body weight), but also display a trend to increased percent adiposity (total WAT weight compared to wild-type controls) suggesting an increase in relative fat mass

• this is not observed in males

increased white adipose tissue mass ( J:162000 )

• total mass of dissected white adipose tissue depots is increased (as % body weight) in doxycycline-treated females compared to saline-treated females

• this is not observed in males

behavior/neurological

behavior/neurological phenotype ( J:162000 )

• no alterations in food intake in 15-week old mutants of either sex is observed with cre induction by intracerebroventricular injection of doxycycline; spontaneous food intake and intake after 24-hour fasting is similar to dox- or saline-treated controls and wild-type

• over a 2-day period as measured by indirect calorimetry after cre induction, male mutants show trend toward increased food intake relative to controls, but females do not

abnormal locomotor activation ( J:162000 )

• treated males do not show any alteration in activity

• after cre induction, females exhibit significantly decreased physical activity over a 2-day period relative to controls

skeleton

increased trabecular bone volume ( J:162000 )

• doxycycline-treated mice show (slight (1.2-fold) but) significant increase in trabecular bone volume as well as trabecular number as determined by micro-CT scan analyses, without change in trabecular thickness

• no differences in cortical bone thickness or volume in distal femur is observed in dox-treated mice compared with controls

homeostasis/metabolism

decreased body temperature ( J:162000 )

• after cre induction, male mutants show trend toward decreased rectal temperature (and increased food intake) relative to controls

• females do not, although the transient weight gain is observed

increased oxygen consumption ( J:162000 )

• analyses over a 2-day period by indirect calorimetry show that female mutants after cre induction) display a significant increase in oxygen consumption notably during light phase with no change in the dark phase

• male mice do not show this or change in respiratory exchange ratio (RER)

abnormal glucose homeostasis ( J:162000 )

• doxycycline-treated females show improved fasting glycemia compared to controls

• doxycycline-treated males do not show this phenotype

increased liver triglyceride level ( J:162000 )

• doxycycline-treated females show an increase in hepatic triglyceride content compared to saline-treated females; in males, triglyceride content is significantly decreased

liver/biliary system

increased liver triglyceride level ( J:162000 )

• doxycycline-treated females show an increase in hepatic triglyceride content compared to saline-treated females; in males, triglyceride content is significantly decreased

renal/urinary system

renal/urinary system phenotype ( J:162000 )

N	• daily water intake in mutants after with cre induction by intracerebroventricular injection of doxycycline is not different from control

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 04/30/2024 MGI 6.23